Reprint requirements: Can be reprinted 24 hours after the first publication, source must be cited.
![]()
![]()
![]()
Recently, BVI Medical, a global leading ophthalmic device companyBVI Medical Announced, itsLeos (Ophthalmic Endoscopic Laser System)Has obtained U.S. FDA 510(k) clearance, officially approved for useGlaucoma Treatment。Leos System Introduces ECP (Endoscopic Cyclophotocoagulation) Surgery, Seamlessly Integrating Into Treatment Processes, Offering Potential Breakthroughs for Glaucoma Patients with Its Unique Minimally Invasive Technology and Revolutionary Visualization Capabilities.According to BVI Medical, this isCurrently the only oneA laser system that solves the problem of aqueous humor production through minimally invasive endocanal surgery to reduce intraocular pressure, and combines endoscopic functionality to provide visualization of ocular anatomical structures.Compared with traditional surgery,Leos endoscope integrated design provides real-time imaging capability of intraocular structures., enabling doctors to perform precise operations under high-definition vision, significantly enhancing the safety and efficiency of surgeries.In March 2025, BVI Medical announced the completion of its collaboration with asset management firm TPG.Raised $1 billion (approximately 7.245 billion RMB) in strategic capital, this financing may be the largest single financing in the ophthalmic device field in recent years.BVI Medical Repays Existing Debt and Optimizes Capital Structure with New Equity from TPG and New Investors, Reducing Financial Leverage and Enabling Greater Flexibility for R&D, Production Expansion, and Market DevelopmentHelp the company accelerate product development and expand its global business footprint。Leos is aIntegrated with endoscope and laser functionsThe advanced ophthalmic surgical equipment is equipped with a miniature camera and optical system in the endoscopic part, which can enter the eye through a small incision and provide a clear surgical field of view; the laser part is used to perform specific treatment operations, such as photocoagulation of ocular tissues.
The system uses a minimally invasive trans-endoscopic surgical approach,Direct ActionTo the ciliary body and other tissues within the eye, reducing the production of aqueous humor, thereby achieving the purpose of lowering intraocular pressure.Compared with traditional methods such as transscleral laser treatment, the Leos system has the following advantages:
- Higher Precision:With the visualization function of endoscopes, doctors can perform laser treatment under direct vision, locate and treat target tissues more precisely, and reduce damage to surrounding normal tissues.
- Minimally Invasive Incision:The procedure adopts an endo-road surgical approach, with a small incision, minimal trauma, fast postoperative recovery, and reduced risk of complications such as infection.
- Good visualization effect:Endoscopes can provide clear and intuitive images of the intraocular structures, allowing doctors to have a more comprehensive and accurate understanding of the ocular anatomy, which helps improve the success rate and safety of surgeries.
- Seamless Integration:The Leos system can be seamlessly integrated into existing ophthalmic surgical procedures, such as being performed simultaneously with other ophthalmic surgeries like cataract surgery, reducing the pain and risks associated with multiple surgeries for patients and improving surgical efficiency.
ECP (Endoscopic Cyclophotocoagulation) SurgeryECP is a laser surgical method for treating glaucoma. It uses an endoscope to guide laser energy to perform photocoagulation on the ciliary body inside the eye, thereby reducing the production of aqueous humor and lowering intraocular pressure.ECP surgery can be used to treat various types of glaucoma, including open-angle glaucoma and closed-angle glaucoma.It can be performed as a standalone procedure or combined with other glaucoma surgeries (such as trabeculectomy, glaucoma drainage tube implantation, etc.) or cataract surgery to enhance treatment outcomes.President and CEO of BVI Medical, Shervin KorangyIndicates,"This milestone achievement demonstrates our unwavering commitment to innovation. Our carefully developed product pipeline is yielding results in multiple regions around the world, including the Leos system in the U.S. market."Driven by the recent completion of a $1 billion financing round and the receipt of several important product approvals in the EU and Asian markets, BVI Medical's momentum continues to strengthen.”# Raised over 7.2 billion yuanBVI Medical is a fast-growing company focused on the ophthalmology field and has been very active in the capital market over the past two years.Continuously improve their product lines and sales channels through mergers and acquisitions., making its ophthalmic solutions more competitive.With TPG's $1 billion investment, not only was BVI Medical's existing debt fully refinanced, but new equity was also introduced, strengthening the company's financial position and injecting strong momentum into its accelerated product innovation and global expansion.- In 2023,BVI Medical Acquires Medical MixMedical Mix is the long-term distributor of BVI Medical intraocular lenses, consumables, and equipment.
- In 2024,Completion of the Acquisition of the Ophthalmic Division of Surgical Specialties Corporation. This acquisition added disposable surgical devices such as high-precision micro-scissors and suture materials, enriching the company's product line.
TPG manages total assets exceeding $246 billion. This investment in BVI Medical not only demonstrates its confidence in the ophthalmic healthcare market but also marks an important step for BVI Medical in challenging the market positions of ophthalmic giants like Alcon and Zeiss.This financing is an important turning point for BVI's development,Not only does it provide strong financial support for its accelerated global expansion, but it also lays a solid foundation for challenging the market position of seasoned suppliers in the ophthalmic medical device field.By promoting the widespread adoption of breakthrough technologies among surgeons worldwide, it is expected to reshape the future of ophthalmic surgery and transform the competitive landscape of the industry.# New Chief Commercial OfficerIn April 2025, BVI Medical announced that it has appointedAndrew ChangAs its new Chief Commercial Officer (CCO), his responsibilities include leading the global sales team, global marketing team, and the commercial team, reporting directly to Shervin Korangy, the company's President and Chief Executive Officer.Andrew Chang has over 20 years of business leadership experience, covering the fields of ophthalmic medical devices and ophthalmic pharmaceuticals. He has served asCarl Zeiss Meditec USAPresident of Carl Zeiss Meditec USA and Global Sales Head of Carl Zeiss' Ophthalmic Devices Division. At Carl Zeiss, he is responsible for leading the development and execution of commercial strategies for a global portfolio of diagnostic and surgical technology products.His previous work experience also includesBausch + Lomb(Bausch + Lomb) held a senior position, serving as the Senior Vice President and General Manager of the U.S. Surgical Division. He also served inOptimedica Corporation(OptiMedica) andYisida Pharmaceutical Company(ISTA Pharmaceuticals) held a leadership position.# About BVI Medical
BVI Medical focuses on the development, manufacturing, and sales of innovative medical devices for cataract, retina, glaucoma, and refractive surgeries.BVI's business covers multiple niche markets such as ophthalmic surgical instruments, intraocular lenses, and minimally invasive surgical equipment, spanning over 90 countries worldwide.Under its umbrella are several well-known brands, including Beaver.®(Surgical blade), Visitec®(Perfusion Tube), Malosa®(Disposable surgical instruments), Vitreq®(Vitreoretinal Surgery Products) and PhysIOL®(High-end intraocular lens).Ophthalmology Solutions Case
Ophthalmic Instruments Industry Research
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)